Carterra Vega Aims to Fuel AI Drug Discovery at Unprecedented Speed

SALT LAKE CITY, UT – February 09, 2026 – Carterra, Inc. today announced a significant leap forward in the technology underpinning modern drug discovery with the launch of its Vega™ platform. The new instrument is the industry’s first High-Throughput Surface Plasmon Resonance (HT-SPR) system to feature 48 parallel channels, a development poised to shatter existing bottlenecks in pharmaceutical research and development.

This innovation promises to deliver a 12-fold increase in throughput compared to current market-leading systems, enabling the analysis of over 20,000 molecular interactions per day. By doing so, the Vega platform fundamentally shifts the role of SPR technology, moving it from a secondary validation tool to a powerhouse for primary screening of vast compound libraries. This shift directly addresses a long-standing challenge for scientists, potentially accelerating the journey from a promising lead to a viable clinical candidate.

Redefining the Speed Limit of Discovery

For years, Surface Plasmon Resonance has been a gold standard for studying the intricate, real-time binding interactions between molecules—a critical step in understanding a drug's potential efficacy and behavior. However, the technology's application in early-stage discovery has been hampered by throughput limitations. Researchers often faced a trade-off between speed and data quality, forcing them to use faster but less precise methods for initial large-scale screens, relegating high-resolution SPR to later-stage characterization of a smaller number of pre-selected candidates.

The Carterra Vega is engineered to eliminate this compromise. Its 48-channel architecture represents a stark contrast to the 8-channel and 16-channel systems offered by competitors such as Cytiva's Biacore and Bio-Rad's Octet platforms. While those systems can process hundreds or a few thousand interactions in a run, Vega’s ability to screen over 20,000 small molecule interactions daily is a paradigm shift. This massive increase in capacity allows scientists to apply the rigor of high-resolution binding analysis to entire libraries at the very beginning of the discovery process.

“One of the greatest challenges scientists face is time: the time required to screen large libraries of small molecules and fragments to find a promising lead,” noted Josh Eckman, Co-Founder and CEO at Carterra, in the company's announcement. “This process has been limited by the capabilities of legacy SPR systems... The Carterra Vega platform is a technological leap forward—a true step change.”

The platform's design includes an internal reference and two binding locations in every channel, providing flexibility for a wide range of label-free applications. With an optional robotic module, the system can operate unattended for days, further compounding its efficiency and allowing research teams to generate massive datasets with minimal hands-on time.

The Data Engine for AI-Driven Pharmaceuticals

Perhaps the most profound impact of the Vega platform will be its role in fueling the artificial intelligence revolution sweeping through the pharmaceutical industry. AI and machine learning (ML) models hold immense promise for accelerating drug discovery, but their predictive power is entirely dependent on the quality and quantity of the data used to train them. A primary bottleneck for AI in drug discovery has been the lack of large, high-resolution, and standardized biological datasets.

Carterra is positioning the Vega as the definitive data-generation engine to solve this problem. By producing unprecedented volumes of high-quality binding kinetics and affinity data, the platform can create the rich datasets needed to train and validate sophisticated AI algorithms. These models can then more accurately predict how novel compounds will interact with disease targets, identify subtle patterns in molecular behavior, and guide chemists toward more promising therapeutic candidates, significantly reducing the costly trial-and-error that has long defined the field.

This synergy is not theoretical. Industry experts have consistently pointed to the need for high-throughput, automated experimental platforms to feed the voracious appetite of AI models. Carterra claims there are no other label-free technologies that can enable AI-driven drug discovery at the scale offered by Vega. This capability could dramatically shorten the timeline for identifying and optimizing leads, a critical factor in a high-stakes industry where speed to market is paramount.

A New Benchmark in a Competitive Field

Carterra, whose platforms are already utilized by all 20 of the world's largest pharmaceutical companies, is making a strategic move to solidify its market leadership. The Vega launch builds upon the company's previous innovations, including the Carterra Ultra® system launched in 2024, by directly addressing the industry's call for massively parallel analysis.

The development process itself underscores the market's readiness for such a device. Carterra collaborated closely with four Key Opinion Leaders (KOLs)—comprising three of the world's largest pharmaceutical companies and a major Contract Research Organization (CRO)—to put the Vega through its paces and optimize its performance for both large and small molecule applications. This close partnership with end-users ensures the platform is tailored to solve real-world research challenges.

The market's confidence is further demonstrated by the immediate adoption of the technology. Carterra is preparing to ship the first purchased Vega unit in the first quarter of this year to one of the collaborating pharma KOLs, a top-10 global pharmaceutical company, where it will be immediately integrated into small molecule discovery workflows.

While Carterra has set a new hardware benchmark, the competitive landscape remains dynamic. Competitors like Cytiva are actively developing their own machine learning software to enhance data analysis from their Biacore systems, and other companies like Bruker are exploring novel label-free technologies. However, Carterra's 48-channel hardware leap presents a formidable advantage in raw data generation capacity.

By enabling high-resolution primary screening and generating data on a scale previously unimaginable, the Vega platform is not just an incremental upgrade but a tool designed to reshape discovery workflows from the ground up. This advancement promises to empower scientists to ask new questions, accelerate their research, and ultimately shorten the path from the laboratory to new clinical therapies.